Technology
DNAtrix is developing potent oncolytic immunotherapies for the treatment of cancer using genetically modified viruses that maximize safety and efficacy.
learn more >
November 26, 2018DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial
November 15, 2018DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma
November 13, 2018DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer
DNAtrix is developing potent oncolytic immunotherapies for the treatment of cancer using genetically modified viruses that maximize safety and efficacy.
learn more >
A pipeline of novel viral-driven immunotherapies is being developed for the treatment of a variety of aggressive cancers.
learn more >
Human clinical trials of DNAtrix therapies are ongoing for adult and pediatric patients diagnosed with aggressive brain tumors.
learn more >
Virus artwork by Luke Jerram